The effect of dobutamine in sepsis: a propensity score matched analysis

Zhu, Youfeng; Yin, Haiyan; Zhang, Rui; Ye, Xiaoling; Wei, Jianrui

doi:10.1186/s12879-021-06852-8

BMC Infectious Diseases

Table 1 Baseline demographic data and clinical characteristics of patients included in the study

From: The effect of dobutamine in sepsis: a propensity score matched analysis

Covariate	Original patients (before matching)			Missing data (%)
Covariate	Non-dobutamine group (N = 2165)	Dobutamine group (N = 121)	P value	Missing data (%)
Age (years)	66.63 ± 17.06	68.57 ± 16.44	0.222	0.0
Gender (Male), n (%)	1208 (55.8%)	74 (61.2%)	0.248	0.0
Height (cm)	168.76 ± 11.00	168.61 ± 9.68	0.883	0.0
Weight (kg)	82.65 ± 27.00	83.26 ± 21.95	0.808	0.0
BMI (kg/m [2])	29.00 ± 9.00	29.13 ± 6.72	0.871	0.0
Temperature (℃)	37.71 ± 1.04	37.87 ± 1.11	0.108	0.4
MAP (mmHg)	51.63 ± 14.01	46.44 ± 15.51	0.000	0.0
HR (beats min⁻¹)	112.71 ± 22.97	118.60 ± 23.46	0.006	0.0
RR (min⁻¹)	30.23 ± 7.11	31.78 ± 8.00	0.020	0.0
SOFA score	7.22 ± 4.00	9.91 ± 3.73	0.000	0.0
SOFA-cardiovascular score	2.26 ± 1.45	3.23 ± 1.20	0.000	0.0
SAPS-I score	21.46 ± 5.68	24.86 ± 5.64	0.000	0.0
SAPS-II score	46.76 ± 16.66	56.59 ± 14.83	0.000	0.0
ECI	10.36 ± 7.91	11.06 ± 7.92	0.342	0.0
Norepinephrine dose (mg)	58.30 ± 82.56	79.89 ± 96.44	0.004	0.0
Norepinephrine use	1269 (58.6%)	110 (90.9%)	0.000	0.0
Urine volume (ml, 1st day)	1565.61 ± 1333.18	1083.63 ± 1005.80	0.000	1.0
Input volume (ml, 1st day)	8209.26 ± 6142.67	9471.47 ± 7166.17	0.069	4.3
Microbiology, n (%)
Positive (%)	1719 (79.4%)	99 (81.8%)	0.521	0.0
Negative	446 (20.6%)	22 (18.2%)	0.521	0.0
Interventions, n (%)
Renal replacement use (1st day)	170 (7.9%)	15 (12.4%)	0.074	0.0
Mechanical ventilation use (1st day)	1128 (52.1%)	95 (78.5%)	0.000	0.0
Comorbidities, n (%)
Congestive heart failure	780 (36.0%)	75 (62.0%)	0.000	0.0
Pulmonary circulation disease	168 (7.8%)	10 (8.3%)	0.840	0.0
Renal failure	469 (21.7%)	23 (19.0%)	0.489	0.0
Diabetes	676 (31.2%)	44 (36.4%)	0.236	0.0
COPD	496 (22.9%)	33 (27.3%)	0.268	0.0
Coagulopathy	614 (28.4%)	53 (43.8%)	0.000	0.0
Fluid electrolyte disorder	1204 (55.6%)	66 (54.5%)	0.818	0.0
Admission type, n (%)
Emergency	2106 (97.3%)	113 (93.4%)	0.014	0.0
Elective	59 (2.7%)	8 (6.6%)	0.014	0.0
Sepsis type, n (%)
Sepsis	451 (20.8%)	7 (5.8%)	0.000	0.0
Severe sepsis	896 (41.4%)	50 (41.3%)		0.0
Septic shock	818 (37.8%)	64 (52.9%)		0.0
Laboratory Tests
Lactate (mmol/L)	2.59 ± 2.19	3.50 ± 2.86	0.001	48.4
Glucose-min	106.90 ± 38.77	108.06 ± 48.17	0.753	0.5
Glucose-max	190.70 ± 94.38	227.50 ± 93.32	0.000	0.5

Data are mean ± SD, median (interquartile) or n (%). SOFA Sequential Organ Failure Assessment, ranging from 0 to 24, with higher scores indicating a greater degree of organ failure; ECI Elixhauser comorbidity index, and we used the modified vanWalraven Elixhauser comorbidity score in our study, which consists of 30 comorbidity diseases, range from − 19 to 89 points, with higher scores indicating a greater risk of hospital mortality, MAP mean arterial pressure; HR: heart rate, RR respiratory rate, SAPS-I simplified acute physiologic score-I, SAPS-II simplified acute physiologic score-II, ICU intensive care unit, COPD chronic obstructive pulmonary disease. The definitions and diagnositic criteria for sepsis, severe sepsis and septic shock were made according to the Surviving Sepsis Campaign Guidelines [1, 13, 14]

Back to article page

ISSN: 1471-2334

Contact us

General enquiries: journalsubmissions@springernature.com